Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Postdoctoral Scientist

Phone: +49 6221 42 3822

Orcid ID: 0000-0002-2266-8621


Scientific CV

Sep 2023 - Dec 2023
Postdoctoral Scientist, Immunotherapy and Immunoprevention, DKFZ, Heidelberg

2019 - 2023
PhD student, jointly between Immunotherapy and Immunoprevention, DKFZ, Heidelberg, Germany and the Cell Biology Research Unit (URBC) – Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium

2017 - 2019
MSc Biochemistry, Cellular and Molecular Biology, Faculty of Science, University of Namur, Namur, Belgium

2014 - 2017
BSc Biomedical Sciences, Faculty of Medicine, University of Namur, Namur, Belgium


Research Project

Investigation of immunological factors contributing to the increased radiosensitivity of HPV-driven compared to HPV-negative head and neck cancer

Despite the fact that several strains of human papillomavirus (HPV) significantly increase the risk to develop malignancies, including head and neck squamous cell carcinoma (HNSCC), the prognosis and treatment response of HPV-driven HNSCC is considerably better than of HPV-negative HNSCC. Importantly, HPV-driven HNSCC exhibit increased radiosensitivity when compared to their HPV-negative counterparts. While cancer cell intrinsic factors partially explain the observed difference, the immune response also seems to play a major role in the differential radiation response.

This project aims to determine if HPV-related immunogenicity of HNSCC cancer cells after irradiation favors an efficient anti-cancer immune response and immune-memory formation, improving HNSCC response to radiation treatment. We address the difference in immunogenicity of HPV-driven and HPV-negative HNSCC before and after radiation, and assess how immunogenic cell death and dendritic cell maturation is changed. With our mass spectrometry (MS)-based epitope detection pipeline, we investigate if there is a connection between the increased radiosensitivity of HPV-driven HNSCC and a possible increased presentation of either HPV-encoded epitopes and/or mutation-derived neoepitopes after irradiation and compared to HPV-negative HNSCC. Finally, the therapeutic relevance of immunogenicity-related radiosensitivity will be determined by combining radiotherapy with immune-checkpoint blockage and therapeutic vaccination in orthotopic mouse models.

Resulting Publications

Development of an Orthotopic HPV16-Dependent Base of Tongue Tumor Model in MHC-Humanized Mice.
Schifflers C, Zottnick S, Förster JD, Kruse S, Yang R, Wiethoff H, Bozza M, Hoppe-Seyler K, Heikenwälder M, Harbottle RP, Michiels C, Riemer AB.  *Equal contributors.
Pathogens. 2023; 12(2):188.

Enhanced radiation sensitivity of human papillomavirus-driven head and neck cancer: focus on immunological aspects.
Özcan-Wahlbrink M, Schifflers C, Riemer AB.
Frontiers in Immunology 2019, 10: 2831.

to top
powered by webEdition CMS